Inventor · disambiguated record
Ragupathy Madiyalakan
Also filed as: MADIYALAKAN RAGUPATHY
16 granted patents·18 pending applications·174 citations·filing 1996–2023
92Inventor score
Top patents by PatentIndex Score
34 records- 0193US6716966B1Therapeutic binding agents against MUC-1 antigen and methods for their useALTAREX INC·Filed 2000·Granted Apr 6, 2004·56 cites·29 claims
- 0285US7147850B2Therapeutic binding agents against MUC-1 antigen and methods for their useALTAREX MEDICAL CORP·Filed 2001·Granted Dec 12, 2006·19 cites·23 claims
- 0383US8454991B2Method and device for photodynamic therapyWOO THOMAS·Filed 2007·Granted Jun 4, 2013·5 cites·11 claims
- 0481US6881405B2Reagents and methods for inducing an immune response to prostate specific antigenALTAREX MEDICAL CORP·Filed 1999·Granted Apr 19, 2005·45 cites·9 claims
- 0581US6241985B1Method and composition for reconforming multi-epitopic antigens to initiate an immune responseALTAREX INC·Filed 1996·Granted Jun 5, 2001·29 cites·14 claims
- 0680US10537636B2Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvantONCOQUEST INC·Filed 2017·Granted Jan 21, 2020·1 cites·6 claims
- 0774US11351255B2Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvantONCOQUEST INC·Filed 2019·Granted Jun 7, 2022·0 cites·11 claims
- 0871US8038994B2Combination therapy for treating diseaseQUEST PHARMATECH INC·Filed 2004·Granted Oct 18, 2011·3 cites·20 claims
- 0971US2008311127A1Combination therapy for treating diseaseALTAREX MEDICAL CORP·Filed 2007·Application pending·0 cites
- 1067US2007036798A1Method and composition for reconforming multi-epitopic antigens to initiate an immune responseALTAREX MEDICAL CORP·Filed 2006·Application pending·0 cites
- 1165US2008131443A1Method and composition for reconforming multi-epitopic antigens to intiate an immune responseALTAREX MEDICAL CORP·Filed 2007·Application pending·0 cites
- 1265US2008206318A1Therapeutic compositions that alter the immune responseMADIYALAKAN RAGUPATHY·Filed 2007·Application pending·0 cites
- 1364US6086873ATherapeutic composition and method of treatmentALTAREX INC·Filed 1997·Granted Jul 11, 2000·10 cites·5 claims
- 1463US8916205B2Polymeric nanoparticles for photosensitizersHADDADI AZITA·Filed 2011·Granted Dec 23, 2014·1 cites·5 claims
- 1563US2020206347A9Method of indirect immunization of human ovarian cancer patients through selection of xenogeneic immunoglobulin fc portionsONCOQUEST INC·Filed 2017·Application pending·0 cites
- 1662US2025066504A1Use of oregovomab and parp inhibitors for treatment of ovarian cancerCANARIABIO INC·Filed 2023·Application pending·0 cites
- 1761US2006159688A1Method for diagnosing efficacy of xenotypic antibody therapyMADIYALAKAN RAGUPATHY·Filed 2004·Application pending·0 cites
- 1859US2024139316A1Use of oregovomab and bevacizumab, paclitaxel, carboplatin for treatment of brca-wild type platinum sensitive recurrentCANARIABIO INC·Filed 2022·Application pending·0 cites
- 1957US7579445B2Reagents and methods for inducing an immune response to prostate specific antigenALTAREX MEDICAL CORP·Filed 2004·Granted Aug 25, 2009·0 cites·9 claims
- 2057US2001036457A1Method and composition for reconforming multi-epitopic antigens to initiate an immune responseFiled 2001·Application pending·0 cites
- 2157US2023070306A1Monoclonal antibodies against her2/neu and uses thereofONCOQUEST PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2257US2008220012A1Therapeutic Compositions that alter the immune responseMADIYALAKAN RAGUPATHY·Filed 2007·Application pending·0 cites
- 2357US2005048059A1Therapeutic binding agents against MUC-1 antigen and methods for their useALTAREX INC·Filed 2004·Application pending·0 cites
- 2457US2009220493A1Reagents and methods for inducing an immune response to prostate specific antigenALTAREX MEDICAL CORP·Filed 2007·Application pending·0 cites
- 2555US2009202560A1Method for diagnosing efficacy of xenotypic antibody therapyALTAREX MEDICAL CORP·Filed 2007·Application pending·0 cites
- 2654US2018221476A1Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvantONCOQUEST NC·Filed 2017·Application pending·0 cites
- 2754US2008019990A1Therapeutic binding agents against MUC-1 antigen and methods for their useMADIYALAKAN RAGUPATHY·Filed 2006·Application pending·0 cites
- 2850US2019322760A1Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancerONCOQUEST INC·Filed 2019·Application pending·0 cites
- 2948US11773183B2MUC16 monoclonal antibody and uses thereofQUEST PHARMATECH INC·Filed 2019·Granted Oct 3, 2023·0 cites·18 claims
- 3046US10392444B2Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancerONCOQUEST INC·Filed 2015·Granted Aug 27, 2019·0 cites·9 claims
- 3142US2010262115A1Nanoparticles for cancer sonodynamic and photodynamic therapyINTELLIGENTNANO INC·Filed 2010·Application pending·0 cites
- 3241US10975163B2Methods of increasing delivery of anti-cancer agents to targetsONCOQUEST INC·Filed 2016·Granted Apr 13, 2021·0 cites·8 claims
- 3336US7361346B1Therapeutic compositions that produce an immune responseALTAREX INC·Filed 1998·Granted Apr 22, 2008·2 cites·37 claims
- 3434US7318921B2Therapeutic compositions that alter the immune responseALTAREX MEDICAL CORP·Filed 1999·Granted Jan 15, 2008·3 cites·76 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →